Daclizumab

Zenapax 5MG/ML

5 MG / ML LiquidCanadaCancelledAuthorised 2 Mar 2000

Open in the registerAsk Osler about it

This page is kept for reference and is not offered to search engines.

In other countries

The same active substances on other registers, the same brand first.

Documents

The official texts, at the regulator.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Daclizumab

Zenapax 5MG/ML

5 MG / ML LiquidCanadaCancelledAuthorised 2 Mar 2000

Open in the registerAsk Osler about it

This page is kept for reference and is not offered to search engines.

In other countries

The same active substances on other registers, the same brand first.

Documents

The official texts, at the regulator.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Register entryHealth Canada

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Health Canada, Canada

Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.

Licence: Open Government Licence Canada · Added 13 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Daclizumab
Strength: 5 MG / ML
Dosage form: Liquid
Route: Intravenous
Register: Canada (Health Canada)
Status: Cancelled
Status in the register: Cancelled Post Market
Authorised: 2 Mar 2000
Registration: DIN 02241473
Marketing authorisation holder: Hoffmann-LA Roche Limited
ATC code: L04AC01
Group: Antineoplastic and immunomodulating agents
Supply: PRESCRIPTION, SCHEDULE D